about
Molecular Genetic of Atopic dermatitis: An UpdateAdvances in understanding and managing atopic dermatitisImmune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted TherapeuticsOrganization, barrier function and antimicrobial lipids of the oral mucosaNew era of biologic therapeutics in atopic dermatitisGenetic and epigenetic studies of atopic dermatitisDefects of corneocyte structural proteins and epidermal barrier in atopic dermatitisEvidence That Loss-of-Function Filaggrin Gene Mutations Evolved in Northern Europeans to Favor Intracutaneous Vitamin D3 ProductionTrichohyalin-like proteins have evolutionarily conserved roles in the morphogenesis of skin appendagesRe-appraisal of current theories for the development and loss of epidermal pigmentation in hominins and modern humansEpidermal barrier defects link atopic dermatitis with altered skin cancer susceptibilityFilaggrin-null mutations are associated with increased maturation markers on Langerhans cells.TSLP is a direct trigger for T cell migration in filaggrin-deficient skin equivalents.Increased cis-to-trans urocanic acid ratio in the skin of chronic spontaneous urticaria patients.Racial comparison of filaggrin null mutations in asthmatic patients with atopic dermatitis in a US population.Exome sequencing of filaggrin and related genes in African-American children with atopic dermatitis.Increased epidermal filaggrin in chronic idiopathic urticaria is associated with severity of urticaria.Associations of childhood eczema severity: a US population-based study.Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis preventionAssociation of filaggrin variants with asthma and rhinitis: is eczema or allergic sensitization status an effect modifier?Downregulation of keratin 76 expression during oral carcinogenesis of human, hamster and mouse.Topical application of delphinidin reduces psoriasiform lesions in the flaky skin mouse model by inducing epidermal differentiation and inhibiting inflammationNo association between loss-of-function mutations in filaggrin and diabetes, cardiovascular disease, and all-cause mortality.Persistence of mild to moderate atopic dermatitis.Maternal filaggrin mutations increase the risk of atopic dermatitis in children: an effect independent of mutation inheritanceSkin barrier dysfunction measured by transepidermal water loss at 2 days and 2 months predates and predicts atopic dermatitis at 1 yearThymic stromal lymphopoietin variation, filaggrin loss of function, and the persistence of atopic dermatitisPHF11 expression and cellular distribution is regulated by the Toll-Like Receptor 3 Ligand Polyinosinic:Polycytidylic Acid in HaCaT keratinocytes.Transcriptome and ultrastructural changes in dystrophic Epidermolysis bullosa resemble skin aging.Protective Effects of Triphala on Dermal Fibroblasts and Human Keratinocytes.Bilateral lower extremity hyperkeratotic plaques: a case report of ichthyosis vulgaris.Impaired Tight Junctions in Atopic Dermatitis Skin and in a Skin-Equivalent Model Treated with Interleukin-17.Structure and evolution of the filaggrin gene repeated region in primatesThe persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohortIn a three-dimensional reconstructed human epidermis filaggrin-2 is essential for proper cornification.Computational analysis of multimorbidity between asthma, eczema and rhinitis.Prevention of atopic dermatitis.The stratum corneum comprises three layers with distinct metal-ion barrier properties.Innate immune responses in house dust mite allergy.Reliability and validity of genotyping filaggrin null mutations.
P2860
Q26752702-B61F7FF5-01E4-4EF0-BE86-D3E07AC01281Q26766224-0FF14BCA-B92A-4BC0-A0E4-41388ECF14A9Q26799532-1E7608B1-DE27-4D50-9B0A-711102CE0A94Q26864922-E2B5E094-1B25-4605-B903-3DCEAE37201BQ27001941-BBF9D30E-1BD8-4E44-8E16-0F8FFA556FBDQ28073454-023C9653-1D3C-4984-85CF-75A46A9BC2A2Q28085608-62CF6661-C7D9-4568-980A-2E06E3C7101CQ28650093-85FEBB4C-AE48-4D94-9826-0BED37920883Q28650131-7DB9A7EB-5EF6-493E-AB52-C108A63990ECQ28703861-A0C7A418-C353-4730-8A69-D007E246DA5FQ33555117-7FD8E4EF-4EB9-4858-97EE-33025165D235Q33650573-941BCFA3-909B-4740-9A3E-FE410CE8C6BDQ33674018-7DE4CC65-A352-49B5-B10B-7135CF2395C0Q33683786-C8BEA8F2-49F2-4154-BBB2-F0EA72B67404Q33874318-4B70B247-D6D7-4BD4-A8DB-15D725DA0F40Q33916764-345832D0-45FE-431C-9F55-6C610C4F5445Q33926863-250D6172-49DF-44E2-8630-7482D7959276Q33988081-F43DD289-9396-4736-AD08-C6F41272ECF7Q34266725-D6260A0A-3DFE-4634-82F6-B2BBF57CC480Q34796072-E9A03118-4B7A-48BA-8A4A-FB921FB5B8D4Q34923391-611C0D69-3D9B-4947-8438-091D0B204195Q35071781-7AD53D72-7429-4CD2-8A2A-82D5AE03F5F3Q35075742-AC0CDCC3-1B97-4936-8C9C-5B133F5F3ED6Q35155669-5958E7DE-8BA1-4C80-B108-16D6DA6C5094Q35165436-B57D0C73-E1A3-4153-B670-22E3536CBDD8Q35243069-136FF9C6-13CC-4E16-A12B-AF3585173171Q35553105-8667E102-9A63-4F83-B77C-E27D0DB79FD0Q35842995-F2E0C246-9A28-4D94-98EF-81FE541BAB9CQ35859768-A63ABEE5-0AC0-4D59-AB4F-EBA5DA0C5DF1Q35885681-DE29A0CF-32A8-41DE-937D-D3B69078EE2CQ36078308-C61033E9-3128-4998-83DF-008D38738092Q36121354-6F1EC3E8-D5FB-4BD0-AE7C-FEBE0257019FQ36246584-97EDD4EB-2C7A-46EF-B5E9-74F6656FA0B2Q36291414-FEEE7561-C4E8-4AAD-BBDC-A79B3E140336Q36347302-51F237FE-FA6F-4FD1-A691-FC4120A54388Q36396910-E0297904-7E57-4DAF-8522-0DE39C40D88CQ36449701-990DC7C9-5B43-4CC3-BA4F-49B473659A1AQ36791961-F2DDDB00-6BCE-4284-838E-B864ACFF5D5BQ36857029-7811E664-CAA6-4F65-BDDC-A40BFF549AFAQ37009417-A1C920BC-95DD-40C7-8BE4-2029ABF4E17B
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
One remarkable molecule: filaggrin.
@ast
One remarkable molecule: filaggrin.
@en
type
label
One remarkable molecule: filaggrin.
@ast
One remarkable molecule: filaggrin.
@en
prefLabel
One remarkable molecule: filaggrin.
@ast
One remarkable molecule: filaggrin.
@en
P2860
P921
P356
P1476
One remarkable molecule: filaggrin
@en
P2093
W H Irwin McLean
P2860
P2888
P304
P356
10.1038/JID.2011.393
P407
P433
P577
2011-12-08T00:00:00Z